| BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation D Rathod, Y Fu, K Patel European Journal of Pharmaceutical Sciences 138, 105039, 2019 | 58 | 2019 |
| Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma Y Fu, D Rathod, K Patel Experimental cell research 396 (1), 112275, 2020 | 31 | 2020 |
| EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma Y Fu, D Rathod, EM Abo-Ali, VV Dukhande, K Patel Pharmaceutics 11 (10), 504, 2019 | 25 | 2019 |
| Lenvatinib-valproic acid self nanoemulsifying preconcentrate for the treatment of liver cancer R Hegazy, D Rathod, A Saraswat, R Vartak, A Muth, K Patel Journal of Molecular Liquids 398, 124263, 2024 | | 2024 |
| ARV-825 D Rathod, Y Fu, K Patel ARV 505, 15, 0 | | |
